Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GPR6 | P46095 | 2/20 | 0.36 |
| ▸ | STS | P08842 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.35 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | BCL9 | O00512 | 1/20 | 0.34 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3563776 | 0.91 | GRIK1 (0.43) | MEN1KMT2AGPR6STSHSD17B10 | |
| SCHEMBL3912796 | 0.89 | GPR6 (0.38) | GPR6KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL7356525 | 0.79 | HIF1A (0.34) | GPR6ALDH1A1KDM2BRAB9APDE4B | |
| SCHEMBL3557510 | 0.79 | GPR6 (0.35) | GPR6GRIK1PDE4B | |
| SCHEMBL3901739 | 0.78 | GPR6 (0.36) | GPR6HSD17B10KDM4EALDH1A1HPGD | |
| SCHEMBL3903288 | 0.78 | GPR6 (0.41) | GPR6KDM4EALDH1A1HPGD | |
| SCHEMBL3151620 | 0.78 | STS (0.55) | MEN1KMT2ASTSALDH1A1PDE4B | |
| SCHEMBL3905636 | 0.76 | GPR6 (0.41) | GPR6KDM4EALDH1A1HPGDRAB9A | |
| SCHEMBL8094956 | 0.76 | LIPG (0.38) | — | |
| SCHEMBL3904985 | 0.75 | MAPT (0.42) | MEN1KMT2AHSD17B10KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700628-B2 | Aromatic ether derivatives useful as thrombin inhibitors | ELI LILLY AND COMPANY (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | ELI LILLY AND COMPANY | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227566-A1 | AROMATIC ETHER DERIVATIVES USEFUL AS THROMBIN INHIBITORS | TFPI, F2, F11 | MEN1 1540/4885KMT2A 2775/4885GPR6 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.